| Income Statement | 2025-06-30 | |||
|---|---|---|---|---|
| Research and development | 9,959 | |||
| General and administrative | 4,500 | |||
| Total operating expenses | 14,459 | |||
| Operating loss | -14,459 | |||
| Interest income, net | 1,075 | |||
| Foreign exchange gain (loss) | -11 | |||
| Research and development incentive income | 127 | |||
| Grant income | 25 | |||
| Total other income, net | 1,216 | |||
| Net loss and comprehensive loss | -13,243 | |||
| Net loss per share, basic | -0.16 | |||
| Net loss per share, diluted | -0.16 | |||
| Weighted average number of shares outstanding, basic | 85,380,587 | |||
| Weighted average number of shares outstanding, diluted | 85,380,587 | |||
ANAVEX LIFE SCIENCES CORP. (AVXL)
ANAVEX LIFE SCIENCES CORP. (AVXL)